SCHEDULE: MAK Capital Discloses 6.3% Stake in ClearPoint Neuro

MAK Capital Fund LP and associated entities have filed an amended Schedule 13G reporting a 6.3% beneficial ownership stake in ClearPoint Neuro, Inc.

Summary

• MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed an amended Schedule 13G regarding their investment in ClearPoint Neuro, Inc.
• The reporting persons collectively hold 1,901,489 shares of common stock.
• This holding represents 6.3% of the total 29,989,563 shares outstanding as of May 7, 2026.
• The filing confirms the shares are held for investment purposes without the intent to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional ownership levels without indicating a change in strategic direction.

Positives

• Institutional investor maintains a significant 6.3% stake, signaling continued interest in the company's long-term prospects.

Negatives

• None identified in this regulatory disclosure.

Risks

• Market volatility affecting the value of the equity position.
• Potential for future changes in investment strategy by the reporting persons.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Management Comments

• The reporting persons certify that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors holding over 5% of a company's stock, reflecting passive investment activity within the medical device and neuro-navigation sector.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for institutional ownership disclosure.
• The 6.3% stake is consistent with typical minority interest positions held by specialized investment funds in small-cap medical technology companies.

Stakeholder Impact

• Provides transparency to shareholders regarding the concentration of ownership by institutional entities.

Next Steps

• Continued monitoring of future SEC filings for any changes in the reporting persons' ownership status.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Schedule 13G, Institutional Ownership, MAK Capital, SEC Filing